AUPH
Aurinia Pharmaceuticals Inc
NASDAQ: AUPH · HEALTHCARE · BIOTECHNOLOGY
$15.72
+3.22% today
Updated 2026-05-11
Market cap
$2.02B
P/E ratio
7.28
P/S ratio
6.78x
EPS (TTM)
$2.16
Dividend yield
—
52W range
$7 – $17
Volume
1.2M
WallStSmart proprietary scores
69
out of 100
Grade: B
Buy
Investment rating
9.3
Growth
A+7.0
Quality
B+9.5
Profitability
A+6.7
Valuation
B4/9
Piotroski F-Score
Moderate
0.9
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →198 stocks currently score above 75
Price targets
Analyst target
$17.00
+8.14%
12-Month target
$17.96
+14.25%
Intrinsic (DCF)
—
Margin of safety
—
0 Strong Buy4 Buy3 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Profit margin 100.00% — above average
+ ROE 65.00% — strong efficiency
+ Free cash flow $32.52M — positive
+ Revenue growth 24.40% QoQ
+ Debt/equity 0.21x — low leverage
Risks
- Altman Z 0.91 — distress zone
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $134.03M | $175.51M | $235.13M | $283.06M | $298.30M |
| Net income | $-108.18M | $-78.02M | $5.75M | $287.20M | $34.35M |
| EPS | — | — | — | — | $2.16 |
| Free cash flow | $-79.82M | $-34.18M | $44.11M | $135.41M | $32.52M |
| Profit margin | -80.71% | -44.45% | 2.45% | 101.47% | 100.00% |
Peer comparison
Smart narrative
Aurinia Pharmaceuticals Inc trades at $15.72. representing a P/E of 7.28x trailing earnings. Our Smart Value Score of 69/100 indicates the stock is good. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of 0.91, it sits in the distress. TTM revenue stands at $298.30M. with profit margins at 100.00%.
Frequently asked questions
What is Aurinia Pharmaceuticals Inc's stock price?
Aurinia Pharmaceuticals Inc (AUPH) trades at $15.72.
Is Aurinia Pharmaceuticals Inc overvalued?
Smart Value Score 69/100 (Grade B, Buy).
What is the price target of Aurinia Pharmaceuticals Inc (AUPH)?
The analyst target price is $17.00, representing +8.1% upside from the current price of $15.72.
What is Aurinia Pharmaceuticals Inc's revenue?
TTM revenue is $298.30M.
Piotroski F-Score?
4/9 — moderate financial health.
Altman Z-Score?
0.91 — distress.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio6.78x
ROE65.00%
Beta1.45
50D MA$15.20
200D MA$13.99
Shares out0.13B
Float0.13B
Short ratio—
Avg volume1.2M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—